Cargando…
Phenotype and Clinical Outcomes of Titin Cardiomyopathy
BACKGROUND: Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification. OBJECTIVES: The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM. METHODS: In this prospective, o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Biomedical
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666113/ https://www.ncbi.nlm.nih.gov/pubmed/29073955 http://dx.doi.org/10.1016/j.jacc.2017.08.063 |
_version_ | 1783275244075614208 |
---|---|
author | Tayal, Upasana Newsome, Simon Buchan, Rachel Whiffin, Nicola Halliday, Brian Lota, Amrit Roberts, Angharad Baksi, A. John Voges, Inga Midwinter, Will Wilk, Alijca Govind, Risha Walsh, Roddy Daubeney, Piers Jarman, Julian W.E. Baruah, Resham Frenneaux, Michael Barton, Paul J. Pennell, Dudley Ware, James S. Prasad, Sanjay K. Cook, Stuart A. |
author_facet | Tayal, Upasana Newsome, Simon Buchan, Rachel Whiffin, Nicola Halliday, Brian Lota, Amrit Roberts, Angharad Baksi, A. John Voges, Inga Midwinter, Will Wilk, Alijca Govind, Risha Walsh, Roddy Daubeney, Piers Jarman, Julian W.E. Baruah, Resham Frenneaux, Michael Barton, Paul J. Pennell, Dudley Ware, James S. Prasad, Sanjay K. Cook, Stuart A. |
author_sort | Tayal, Upasana |
collection | PubMed |
description | BACKGROUND: Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification. OBJECTIVES: The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM. METHODS: In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events. RESULTS: Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m(2) reduction; p(adjusted) = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv(+/−) groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82). CONCLUSIONS: In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis. |
format | Online Article Text |
id | pubmed-5666113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier Biomedical |
record_format | MEDLINE/PubMed |
spelling | pubmed-56661132017-11-09 Phenotype and Clinical Outcomes of Titin Cardiomyopathy Tayal, Upasana Newsome, Simon Buchan, Rachel Whiffin, Nicola Halliday, Brian Lota, Amrit Roberts, Angharad Baksi, A. John Voges, Inga Midwinter, Will Wilk, Alijca Govind, Risha Walsh, Roddy Daubeney, Piers Jarman, Julian W.E. Baruah, Resham Frenneaux, Michael Barton, Paul J. Pennell, Dudley Ware, James S. Prasad, Sanjay K. Cook, Stuart A. J Am Coll Cardiol Article BACKGROUND: Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification. OBJECTIVES: The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM. METHODS: In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events. RESULTS: Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m(2) reduction; p(adjusted) = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv(+/−) groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82). CONCLUSIONS: In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis. Elsevier Biomedical 2017-10-31 /pmc/articles/PMC5666113/ /pubmed/29073955 http://dx.doi.org/10.1016/j.jacc.2017.08.063 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tayal, Upasana Newsome, Simon Buchan, Rachel Whiffin, Nicola Halliday, Brian Lota, Amrit Roberts, Angharad Baksi, A. John Voges, Inga Midwinter, Will Wilk, Alijca Govind, Risha Walsh, Roddy Daubeney, Piers Jarman, Julian W.E. Baruah, Resham Frenneaux, Michael Barton, Paul J. Pennell, Dudley Ware, James S. Prasad, Sanjay K. Cook, Stuart A. Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title | Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title_full | Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title_fullStr | Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title_full_unstemmed | Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title_short | Phenotype and Clinical Outcomes of Titin Cardiomyopathy |
title_sort | phenotype and clinical outcomes of titin cardiomyopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666113/ https://www.ncbi.nlm.nih.gov/pubmed/29073955 http://dx.doi.org/10.1016/j.jacc.2017.08.063 |
work_keys_str_mv | AT tayalupasana phenotypeandclinicaloutcomesoftitincardiomyopathy AT newsomesimon phenotypeandclinicaloutcomesoftitincardiomyopathy AT buchanrachel phenotypeandclinicaloutcomesoftitincardiomyopathy AT whiffinnicola phenotypeandclinicaloutcomesoftitincardiomyopathy AT hallidaybrian phenotypeandclinicaloutcomesoftitincardiomyopathy AT lotaamrit phenotypeandclinicaloutcomesoftitincardiomyopathy AT robertsangharad phenotypeandclinicaloutcomesoftitincardiomyopathy AT baksiajohn phenotypeandclinicaloutcomesoftitincardiomyopathy AT vogesinga phenotypeandclinicaloutcomesoftitincardiomyopathy AT midwinterwill phenotypeandclinicaloutcomesoftitincardiomyopathy AT wilkalijca phenotypeandclinicaloutcomesoftitincardiomyopathy AT govindrisha phenotypeandclinicaloutcomesoftitincardiomyopathy AT walshroddy phenotypeandclinicaloutcomesoftitincardiomyopathy AT daubeneypiers phenotypeandclinicaloutcomesoftitincardiomyopathy AT jarmanjulianwe phenotypeandclinicaloutcomesoftitincardiomyopathy AT baruahresham phenotypeandclinicaloutcomesoftitincardiomyopathy AT frenneauxmichael phenotypeandclinicaloutcomesoftitincardiomyopathy AT bartonpaulj phenotypeandclinicaloutcomesoftitincardiomyopathy AT pennelldudley phenotypeandclinicaloutcomesoftitincardiomyopathy AT warejamess phenotypeandclinicaloutcomesoftitincardiomyopathy AT prasadsanjayk phenotypeandclinicaloutcomesoftitincardiomyopathy AT cookstuarta phenotypeandclinicaloutcomesoftitincardiomyopathy |